Printer Friendly

Xcovery Commences Phase 2 Clinical Trial for Ensartinib in Certain Melanoma Patients.

M2 PHARMA-February 9, 2018-Xcovery Commences Phase 2 Clinical Trial for Ensartinib in Certain Melanoma Patients

(C)2018 M2 COMMUNICATIONS

- US-based cancer therapeutics developer Xcovery has initiated its Phase 2 clinical trial of ensartinib (X-396), the company's lead anaplastic lymphoma kinase drug candidate, in patients with advanced malignant melanoma harboring alterations in ALK, including ALKATI, the company said.

The primary objective of the study is to determine the clinical benefit rate (CBR) of ensartinib in this patient population. CBR is defined as any confirmed objective response by Response Evaluation in Solid Tumors (RECIST) 1.1 or stable disease until the 24-week assessment.

This is an open label, single arm Phase 2 study, enrolling patients with melanoma either currently or previously having received a PD-1 based therapy and, if BRAF V600 mutated, a BRAF-based therapy.

The study is comprised of two portions: the screening phase and treatment phase. In the screening phase, archival tumor tissues from patients deemed to be current or future candidates for this trial will be tested for the ALKATI alteration using a Nanostring-based RNA assay at MSK. Patients whose tumors express ALKATI will be eligible for the treatment phase.

Ensartinib (X-396) is a potent anaplastic lymphoma kinase inhibitor currently in a global Phase 3 trial in ALK positive non-small cell lung cancer patients. Besides ALK, ensartinib also potently inhibits TRKA fusions, TRKC, ROS1, EphA2, and c-MET.

Xcovery is working to improve the lives of patients with cancer by discovering medicines to fight advanced tumors. Xcovery is developing a pipeline of oncology therapies to target a wide range of advanced tumors.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Feb 9, 2018
Words:273
Previous Article:Novo Nordisk's Ozempic receives marketing approval in the EU for the treatment of type 2 diabetes.
Next Article:US FDA Grants Gilead Approval for Biktarvy for Treatment of HIV-1 Infection.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters